#6: Boston Scientific (BSX)
Boston Scientific (BSX) manufacturers a wide array of medical devices for use in cardiovascular treatments, diagnostic tests, women’s health and other areas. And unlike the high-growth story of Gilead, BSX is instead a healthcare turnaround story. Shares remain down about 70% from their all-time highs in 2004 and still down significantly from 2007 highs. But a combination of cost-cutting and industry-wide trends have conspired to lift the stock.
A 2011 restructuring strategy and subsequent job cuts have helped improve margins, and at the same time investors are very optimistic about the Affordable Care Act (a.k.a. Obamacare) providing greater access to Boston Scientific devices. After all, if more people have more health insurance than this medical device stock will have more “customers.” Boston Scientific is soundly profitable in 2013 after a few years of losses, and investors have noticed.